论文部分内容阅读
目的探讨不同药物治疗80例围绝经期乳腺癌患者的疗效。方法 80例乳腺癌术后患者,按随机数字表法分为阿那曲唑组和他莫昔芬组,各40例。阿那曲唑组患者在乳腺癌术后服用阿那曲唑治疗。他莫昔芬组患者在乳腺癌术后服用他莫昔芬治疗。在患者术后、治疗6个月以及疗程结束时使用阴道超声检测所有研究对象子宫内膜厚度以及进行子宫内膜活检。结果阿那曲唑组手术后、治疗6个月以及治疗12个月子宫内膜厚度分别为(6.2±1.7)、(5.8±1.1)、(5.2±0.8)mm,他莫昔芬组手术后、治疗6个月以及治疗12个月子宫内膜厚度分别为(6.3±1.6)、(6.5±1.2)、(6.7±0.9)mm,两组手术后子宫内膜厚度差异无统计学意义(P>0.05),两组治疗6个月以及治疗12个月子宫内膜厚度差异有统计学意义(P<0.05)。阿那曲唑组和他莫昔芬组治疗结束时子宫内膜活检阳性分别为0、12.5%,差异有统计学意义(P<0.05)。结论雌激素受体阳性的乳腺癌术后患者服用阿那曲唑不仅能抑制子宫内膜的增厚,还能减少术后肿瘤的复发,效果优于他莫昔芬。
Objective To investigate the efficacy of different drugs in treating 80 patients with perimenopausal breast cancer. Methods Eighty patients with postoperative breast cancer were randomly divided into anastrozole group and tamoxifen group, 40 cases in each group. Patients in the anastrozole group received anastrozole postoperatively for breast cancer. Patients in the tamoxifen group were treated with tamoxifen after breast cancer surgery. All subjects were tested for endometrial thickness and for endometrial biopsy using a transvaginal ultrasound at 6 months after treatment and at the end of treatment. Results After an operation of anastrozole group, the thickness of endometrium was (6.2 ± 1.7), (5.8 ± 1.1) and (5.2 ± 0.8) mm respectively after 6 months of treatment and 12 months of treatment. After the operation of tamoxifen group, The endometrial thickness at 6 months and 12 months of treatment were (6.3 ± 1.6) and (6.5 ± 1.2) and (6.7 ± 0.9) mm, respectively. There was no significant difference in endometrial thickness between the two groups after operation (P> 0.05). There was significant difference in endometrial thickness between the two groups for 6 months and for 12 months (P <0.05). The positive rates of endometrial biopsy at the end of anastrozole and tamoxifen groups were 0 and 12.5%, respectively, with statistical significance (P <0.05). Conclusion Anastrozole after estrogen receptor-positive breast cancer surgery can not only inhibit the thickening of the endometrium, but also reduce the recurrence of the tumor after surgery, the effect is better than tamoxifen.